BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
|Articles|August 1, 2001
- Pharmaceutical Technology-08-01-2001
- Volume 2001 Supplement
- Issue 2
The Squeeze in Contract Manufacturing
Author(s)Scott Fogerty, Roger Lias
The demand for CGMP production of biopharmaceuticals is at an all-time high.
Advertisement
Articles in this issue
about 25 years ago
Creating a Successful Partnership with a Contract Manufacturerabout 25 years ago
Outsourcing Outlookabout 25 years ago
Creative Solutions in Client-CRO Relationshipsabout 25 years ago
Third-Party Technology Transferabout 25 years ago
Stakes Rise for Blown Batchesabout 25 years ago
Partnerships in Drug DiscoveryAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5